You don't have javascript enabled. Please Enabled javascript for better performance.

IndioLabs- addressing clinical needs

23 Aug 2016


IndioLabs is a Bangalore based medical device startup which was foundedwith the goal of identifying specific clinical needs in India and other emerging markets.A multi-disciplinary team invented the BioScoop™ biopsy system and the BxSeal™ technology during their fellowship year under the Stanford-India Biodesign (SIB) Program at All India Institute of Medical Sciences. The SIB Program is a flagship biomedical technology innovation program sponsored by the Department of Biotechnology, under the Ministry of Science and Technology, Government of India. IndioLabs received partial funding from the Biotechnology Ignition Grant scheme of the Biotechnology Industry Research Assistance Council (BIRAC), which helped to bridge the gap between discovery and invention by taking our technologies closer to realization and hospitals.IndioLabsacquired an exclusive global license for these technologies from the Department of Biotechnology (DBT), Government of India, for further development and commercialization in Indian and global markets.

The BioScoop™ biopsy systemrepresents an exciting new approach to percutaneous aspiration biopsy. It is designed to enable physicians to achieve safer and definitive tissue capture using a novel needle design, advanced needle-tissue characterization, and automated control. IndioLabs has also developed the BxSeal™ technology for controlled, concurrent delivery of hemostatic agents during the biopsy procedure that allows for immediate hemostatic action against internal bleeding, and will provide a significant safety advantage over competitive products.The seamless integration of BioScoop™ and BxSeal™ technologies provides consistent tissue samples with a minimal risk of internal bleeding. The device has low requirements on operator skill, and will reduce the cost of procedure, providing affordable care to patients.

indolabs 1

These platform technologies are expected to greatly increase physician adoption of aspiration needle biopsy to appropriately treat and manage curable diseases.At IndioLabs, our value proposition focuses on affordability and big impact providing improved access to care and bringing effective diagnostic solutions to patients in “secondary care settings”.

The BioScoop™ biopsy system was showcased during the launch of the Startup India conference at Vigyan Bhavan. The features and benefits of the device was explained by Dr. Balram Bhargava, Executive Director, School of International Biodesign, All India Institute of Medical Sciences, New Delhi to honorable Prime Minister Narendra Modi.

indolabs 2

indolabs 3

– Siraj Bagwan

Founder and Managing Director


Total Comments - 0

Leave a Reply